SKYEPHARMA AND ENDO AGREE TO TERMINATE JOINT DEVELOPMENT OF PROPOFOL IDD-D FOR NORTH AMERICA

SkyePharma PLC announces today that it has agreed with its North American partner Endo Pharmaceuticals to terminate the joint development of Propofol IDD-D, an injectable anaesthetic and sedative that was licensed to Endo in December 2002. SkyePharma is evaluating its options worldwide for this product, which remains under strategic review.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-21-2006/0004344536&EDATE=)